As Redhill Biopharma Ltd. suggested it might move the needle on treating Helicobacter pylori (H. pylori) bacterial infection, the company's shares (NASDAQ:RDHL) sizzled, as well, hitting an historic high of $22.22 before closing Monday at $19.07 for a gain of $2.61, or 15.9 percent.